Fig. 5

The impact of bestatin on cell function in human glioblastoma cell lines. (A-D) Quantitative analysis of CD13 activity following bestatin treatment (500 µg/mL) is depicted (n = 3, independent cell preparations). (E-H) Cell growth curves at 24 and 48 h after treatment with 0, 62.5, 125, 250, 500 µg/mL bestatin (n = 6 wells/condition of two independent experiments). Statistics relative to 0 h. (I-L) Representative images of the cell scratch assay at starting point (0 h), at 12 and 24 h. Scale bars, 400 μm. (M) Quantification of the percentage of wound closure at 12 and 24 h (250 µg/mL bestatin). (n = 6 wells/condition of two independent experiments). (N-Q) Quantification and representative images of colony formation following bestatin treatment (250 µg/mL) are depicted (n = 3 wells/condition; one representative experiment of three independent experiments is shown). *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired Student’s t-test). CD13^h, high CD13 expression; CD13^m, medium CD13 expression; CD13^l, low CD13 expression